



AHPWA23AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/601,968 Confirmation No.: 8810
Applicant : Fensome et al.
Filed : June 23, 2003
TC/A.U. : 1614
Examiner : B. Kwon
Customer No. : 38199
Title : CYCLOTHIOCARBAMATE DERIVATIVES AS
PROGESTERONE RECEPTOR MODULATORS AND
METHODS OF TREATING SKIN DISORDERS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08B is attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted less than three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account Number 08-3040.

06/02/2006 TBESHAH1 00000003 10601968
02 FC:1806

180.00 OP

Express Mail No. EQ543967191US

REMARKS


Listed below is a document cited in an Office Action dated February 17, 2006 issued in the counterpart Taiwanese Patent Application No. 92116986. A copy of an English translation of the Office Action is enclosed as document AT, together with a copy of the following document.


(AS) VAN VLOTEN et al., "The Effect of 2 Combined Oral Contraceptives Containing Either Drospirenone or Cyproterone Acetate on Acne and Seborrhea", Cutis 69: 2 (April, 2002)

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON

By 
Cathy A. Kedroff
Registration No. 33,980
Suite 210
501 Office Center Drive
Fort Washington, PA 19034
Telephone: (215) 540-9200
Telefacsimile: (215) 540-5818



Approved for use through 06/30/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/601,968
				Filing Date	June 23, 2003
				First Named Inventor	Fensome et al.
				Art Unit	1614
				Examiner Name	B. Kwon
Sheet	1	of	1	Attorney Docket Number	AHPWA23AUSA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AS	VAN VLOTEN et al., "The Effect of 2 Combined Oral Contraceptives Containing Either Drospirenone or Cyproterone Acetate on Acne and Seborrhea", Cutis 69: 2 (April, 2002)	
	AT	English translation of an Office Action dated February 17, 2006 issued in counterpart Taiwanese Patent Application No. 92116986	
	AU	English translation of an Office Action dated March 3, 2006 issued in counterpart Chinese Patent Application No. 03815194.4	
	AV	English translation of an Office Action dated March 3, 2006 provided by our agent in counterpart Chilean Patent Application No. 1280/2003	
	AW	FENSOME et al., "Synthesis and Structure-Activity Relationship of Novel 6-Aryl-1,4-Dihydrobenzo[d][1,3]oxazine-2-thiones as Progesterone Receptor Modulators Leading to the Potent and Selective Nonsteroidal Progesterone Receptor Agonists Tanaproget", J. Med. Chem, 48:5092-5095 (2005)	
	AX	ZHANG et al., "Novel 6-Aryl-1,4-Dihydrobenzo[d][1,3]oxazine-2-thiones as Potent, Selective, and Orally Active Nonsteroidal Progesterone Receptor Agonists", Bioorg. & Med. Chem. Lett., 13:1313-1316 (2003).	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.